Loading...
•
Mar 31, 2023
NextCure Q1 2023 Earnings Report
NextCure's financial position decreased, with a net loss, but remained optimistic about pipeline advancement and clinical milestones.
Key Takeaways
NextCure reported its Q1 2023 financial results, including a net loss of $16.1 million, and R&D expenses of $11.6 million. The company's cash, cash equivalents, and marketable securities were $145.5 million as of March 31, 2023, expected to fund operations into mid-2025. Clinical data readouts are expected in 2023 for NC410, NC762, and NC525 programs.
Cash, cash equivalents, and marketable securities totaled $145.5 million on March 31, 2023.
The first patient was dosed with NC525 in a Phase 1 trial for acute myeloid leukemia (AML).
Net loss for the quarter was $16.1 million.
The company expects to fund operations into mid-2025 with current cash reserves.
Forward Guidance
NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into mid-2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...